Compare VVOS & EVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VVOS | EVGN |
|---|---|---|
| Founded | 2016 | 1999 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Agricultural Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.6M | 9.6M |
| IPO Year | 2020 | 2013 |
| Metric | VVOS | EVGN |
|---|---|---|
| Price | $0.80 | $0.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $2.75 | ★ $3.50 |
| AVG Volume (30 Days) | ★ 277.9K | 43.7K |
| Earning Date | 04-15-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 6.76 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $17,443,000.00 | N/A |
| Revenue This Year | $69.66 | N/A |
| Revenue Next Year | N/A | $73.33 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 16.05 | N/A |
| 52 Week Low | $0.81 | $0.72 |
| 52 Week High | $7.40 | $2.42 |
| Indicator | VVOS | EVGN |
|---|---|---|
| Relative Strength Index (RSI) | 31.74 | 39.28 |
| Support Level | N/A | $0.72 |
| Resistance Level | $1.50 | $1.23 |
| Average True Range (ATR) | 0.11 | 0.05 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 2.62 | 13.36 |
Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. It holds several subsidiaries utilizing the CPB platform for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. It generates maximum revenue from the industrial segment, followed by Agriculture.